• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Inovio shares down on missed Q2 projections as it moves forward with COVID-19 vaccine

August 10, 2021 By Sean Whooley

Inovio PharmaceuticalsInovio Pharmaceuticals (NSDQ:INO) shares took a hit this morning on second-quarter results that missed the consensus forecast.

INO shares were down more than –11% at $8.53 per share in morning trading today.

The Plymouth Meeting, Pa.–based company posted losses of -$82.1 million on sales of $272,824 for the three months ended June 30, 2021, for a 36.2% bottom-line gain on sales growth of 2.1%.

Earnings per share came in at -39¢, 14¢ behind Wall Street, where analysts were looking for sales of $1.21 million.

“With COVID-19 rates surging again globally and an increasing number of breakthrough infections, Inovio recognizes the need for additional safe and effective first-line vaccines, particularly those which could offer potential boosting capabilities, to combat the spread of the virus and emerging variants, including the rapidly spreading delta variant,” Inovio president and CEO Dr. J. Joseph Kim said in a news release. “INO-4800’s ability to generate CD8 T cells are important to mitigating against variants of concern, including the delta variant.

“Findings from a study using clinical samples showed that INO-4800 maintained a robust T cell level against the delta variant when compared to T-cell responses from the original wildtype strain. These findings further complement our previously published Phase 1 and 2 trial data for INO-4800.”

Kim also noted that the advantages of its DNA medicines platform are integral to the company’s ongoing conversations with countries set to participate in its global Phase 3 trial for INO-4800. He added that some of those countries are considering the vaccine candidate for clinical trials and eventual emergency use authorization.

Inovio did not offer financial guidance for the remainder of the year.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Inovio Pharmaceuticals

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS